CND Life Sciences has secured growth financing led by S-Curve Partners to enhance its neurodiagnostics platform, specifically targeting its Syn-One Test, a skin biopsy-based test for detecting biomarkers related to neurodegenerative diseases like Parkinson’s and Lewy body dementia. Over 4,000 clinicians have utilized the test, supporting over 60,000 patients since its inception. The new funding will facilitate the platform’s growth, promote commercial initiatives, and foster partnerships, while aiming to integrate the test into a multimodal biomarker system for improved diagnosis. The financing comes amid a growing focus on biomarkers and precision medicine in neurology, highlighting the need for accurate diagnostics in the field.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://clpmag.com/diagnostic-technologies/cnd-life-sciences-growth-financing-neurodiagnostics-platform/
